Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

AstraZeneca’s Truqap granted MHRA approval to treat advanced breast cancer

Approximately 56,800 new cases of breast cancer are diagnosed in the UK every year

- PMLiVE

Vertex and Orum partner on gene editing conditioning drugs in deal worth $945m

The agreement gives Vertex the rights to use Orum’s targeted protein degradation technology

- PMLiVE

UK government announces national RSV vaccination programme for infants and older adults

The respiratory virus accounts for about 30,000 hospitalisations in children under five every year in the UK

- PMLiVE

Pliant Therapeutics’ bexotegrast shows promise in rare liver disease patients

Primary sclerosing cholangitis affects more than 100,000 people worldwide

Say Communications wins Communique award 2024

Say Wins Communiqué Agility, Flexibility And Transformation Award For Corporate Comms During Geopolitical Upheaval

SAY took home the Agility, Flexibility and Transformation Award at the prestigious Communiqué Awards on 4 July 2024 in recognition of the communications support provided The Royal College of Occupational...

Say Communications

Bayer symbol

Bayer/Orion’s darolutamide combination shows promise in phase 3 prostate cancer trial

The results from the study will support regulatory applications for wider use of the drug

- PMLiVE

Vertex and Genomics expand collaboration to accelerate precision medicines

The partners have been working together since 2018 to develop treatments for serious diseases

- PMLiVE

Camurus shares positive late-stage results for investigational acromegaly treatment

The rare disease has an estimated prevalence of approximately 60 cases per million

- PMLiVE

AI tool better predicts progress of Alzheimer’s versus current clinical tests

The most common form of dementia accounts for up to 80% of all cases

- PMLiVE

Pfizer to advance once-daily formulation of oral GLP-1 receptor agonist danuglipron

The drugmaker said last year that it would be dropping its twice-daily formulation of the candidate

- PMLiVE

Lexeo’s gene therapy candidate shows promise in Friedreich’s ataxia cardiomyopathy

The neurodegenerative movement disorder affects approximately one in every 40,000 people

- PMLiVE

ICR study reveals Lynparza could treat more advanced prostate cancer patients

Up to 30% of men living with the advanced disease have tumours that contain defects in repairing DNA

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links